Results from the DESTINATION Phase III extension trial showed Tezspire (tezepelumab) demonstrated an overall long-term safety and efficacy profile consistent with the previous PATHWAY Phase II and NAVIGATOR Phase III trials, sustained over 104 weeks in a broad population of patients with severe asthma.
Under development by UK pharma major AstraZeneca (LSE: AZN) and US biotech Amgen’s (Nasdaq: AMGN), Tezspire is the first and only biologic for severe asthma with two-year placebo-controlled safety and efficacy data. It was first approved in the USA in December 2021. SVB Securities analysts at that time forecast that Tezspire will generate revenue of $584 million in 2023, growing to $1.0 billion by 2025 and ultimately to $2.6 billion in 2030.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze